7,640.00

+26.00

+0.34%

52,070.00

+152.00

+0.29%

28,728.25

+194.25

+0.68%

Russell 2000 Futures

2,834.20

+12.90

+0.46%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,917.20

+18.30

+0.47%

78,503.99

+917.89

+1.18%

Crude Oil Dec 26

101.65

-2.47

-2.37%

US Private Equity

10,850.63

-82.20

-0.75%

ASX - Delayed Quote AUD

Clarity Pharmaceuticals Ltd (CU6.AX)

1.4770 -0.0930 (-5.92%)

As of 11:48:36 AM GMT+11. Market Open.

Loading Chart for CU6.AX

Chart Range Bar

Interval:

In partnership with ChartIQ

Registrational Phase III CLARIFY trial: Target number of participants achieved

Registrational Phase III CLARIFY trial: Target number of participants achieved

SECuRE update: recruitment target of the Cohort Expansion Main Group achieved

SECuRE update: recruitment target of the Cohort Expansion Main Group achieved

Why Clarity Pharmaceuticals (ASX:CU6) Is Up 11.7% After Investor Focus On Copper Cancer Theranostics

Why Clarity Pharmaceuticals (ASX:CU6) Is Up 11.7% After Investor Focus On Copper Cancer Theranostics

Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma

Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma

Co-PSMA data published in the European Urology journal

Co-PSMA data published in the European Urology journal

3 ASX Growth Stocks With Insider Ownership Expecting Up To 50% ROE

3 ASX Growth Stocks With Insider Ownership Expecting Up To 50% ROE

Clarity Pharmaceuticals Announces SECuRE Trial Update on 8 GBq 67Cu-SAR-bisPSMA dose level with two additional complete responses

Clarity Pharmaceuticals Announces SECuRE Trial Update on 8 GBq 67Cu-SAR-bisPSMA dose level with two additional complete responses

ASX Growth Leaders With Insider Stakes May 2026

ASX Growth Leaders With Insider Stakes May 2026

ASX Growth Companies With High Insider Ownership In April 2026

ASX Growth Companies With High Insider Ownership In April 2026

ASX Growth Companies With Significant Insider Ownership

ASX Growth Companies With Significant Insider Ownership

Radioligand Therapies Market Set for Significant Growth by 2034, Driven by Rising Cancer Burden and Targeted Radiopharmaceutical Innovation | DelveInsight

Radioligand Therapies Market Set for Significant Growth by 2034, Driven by Rising Cancer Burden and Targeted Radiopharmaceutical Innovation | DelveInsight

Mobilize your Website

View Site in Mobile | Classic

Share by: